Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food […]
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes […]
Jubilant Therapeutics Inc. Announces US FDA Clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for Treatment of Solid Tumors With Brain Metastases and Primary Brain Tumors
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical […]
H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials
H1, the connecting force for global HCP, clinical, scientific, and research information, and Lokavant, the […]
LifeNet Health LifeSciences Launches New, Human-relevant Cell-based Assay Service for Drug and Compound Discovery
LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based […]
GSK Signs Agreement to Support Pandemic Preparedness in Europe
GSK plc (LSE/NYSE: GSK) today announced it had signed a framework contract with the European […]
ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology
ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of […]
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that […]
Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA
Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food […]
Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate Into Clinical Trials
Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1-focused […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more